BRAF internal deletions and resistance to BRAF/MEK inhibitor therapy

BRAF and MEK inhibitors have improved clinical outcomes in advanced, BRAF(V600)-mutated melanomas. Acquired resistance occurs in most patients, with numerous and diverse drivers. We obtained pre-treatment and progression biopsies from a patient who progressed on dabrafenib and trametinib. In additio...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Pigment Cell Melanoma Res
Auteurs principaux: Johnson, Douglas B., Childress, Merrida A., Chalmers, Zachary R., Frampton, Garrett M., Ali, Siraj M., Rubinstein, Samuel M., Fabrizio, David, Ross, Jeffrey S., Balasubramanian, Sohail, Miller, Vincent A., Stephens, Philip J., Sosman, Jeffrey A., Lovly, Christine M.
Format: Artigo
Langue:Inglês
Publié: 2017
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5889338/
https://ncbi.nlm.nih.gov/pubmed/29171936
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/pcmr.12674
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires